MiNK Therapeutics Faces Delisting Concerns
Ticker: INKT · Form: 8-K · Filed: Sep 13, 2024 · CIK: 1840229
Sentiment: bearish
Topics: delisting, compliance, regulatory
TL;DR
MiNK Therapeutics might get delisted, big trouble for shareholders.
AI Summary
MiNK Therapeutics, Inc. filed an 8-K on September 13, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company was formerly known as AgenTus Therapeutics, Inc. and changed its name on January 12, 2021. The filing indicates potential issues with its continued listing on a stock exchange.
Why It Matters
This filing signals potential financial distress or non-compliance with exchange rules, which could lead to the stock being removed from trading, impacting investors.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards is a severe indicator of financial or operational problems that could lead to the stock becoming untradeable.
Key Numbers
- 001-40908 — SEC File Number (Identifies the company's filing history with the SEC.)
- 20240913 — Report Date (Date of the earliest event reported in the filing.)
Key Players & Entities
- MiNK Therapeutics, Inc. (company) — Registrant
- AgenTus Therapeutics, Inc. (company) — Former Company Name
- 20240913 (date) — Filing Date
- 212-994-8250 (phone_number) — Registrant's Telephone Number
- 149 Fifth Avenue Suite 500 (address) — Principal Executive Offices
FAQ
What specific listing rule or standard has MiNK Therapeutics failed to satisfy?
The filing does not specify the exact rule or standard that MiNK Therapeutics has failed to satisfy, only that it is a 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard'.
What is the expected timeline for any potential delisting action?
The filing does not provide a specific timeline for any potential delisting action, only that it is a notice of the failure to satisfy a continued listing rule.
Has MiNK Therapeutics taken any steps to address the listing deficiency?
The provided text of the 8-K filing does not mention any specific steps taken by MiNK Therapeutics to address the listing deficiency.
What was MiNK Therapeutics' former name and when did the name change occur?
MiNK Therapeutics, Inc. was formerly known as AgenTus Therapeutics, Inc., and the date of the name change was January 12, 2021.
Where is MiNK Therapeutics, Inc. headquartered?
MiNK Therapeutics, Inc.'s principal executive offices are located at 149 Fifth Avenue, Suite 500, New York, New York 10010.
Filing Stats: 551 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-09-13 16:05:08
Key Financial Figures
- $0.00001 — ch registered Common Stock, par value $0.00001 per share INKT The Nasdaq Stock Mar
- $35.0 m — isted Securities ("MVLS") was less than $35.0 million, as required by Nasdaq Listing Ru
- $35.0 million — the Company's MVLS must meet or exceed $35.0 million for a minimum of ten consecutive tradin
Filing Documents
- inkt-20240913.htm (8-K) — 36KB
- 0000950170-24-106345.txt ( ) — 150KB
- inkt-20240913.xsd (EX-101.SCH) — 25KB
- inkt-20240913_htm.xml (XML) — 5KB
01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. Nasdaq MVLS Notice On September 13, 2024, MiNK Therapeutics, Inc. (the "Company") received a letter (the "MVLS Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying it that for the previous 30 consecutive trading days the Company's Minimum Value of Listed Securities ("MVLS") was less than $35.0 million, as required by Nasdaq Listing Rule 5550(b)(2) (the "MVLS Rule"). Nasdaq has provided the Company with 180 calendar days, or until March 12, 2025, to regain compliance. To regain compliance, the Company's MVLS must meet or exceed $35.0 million for a minimum of ten consecutive trading days. In the event the Company does not regain compliance with the MVLS Rule prior to the expiration of the compliance period, it will receive written notification that its securities are subject to delisting. At that time, the Company may appeal the delisting determination to a Hearings Panel. The Company will continue to monitor its MVLS and consider its available options to regain compliance with the MVLS Rule. However, there can be no assurance that the Company will be able to regain compliance with the MVLS Rule .
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MiNK Therapeutics, Inc. Date: September 13, 2024 By: /s/ Jennifer Buell, Ph.D. Jennifer Buell, Ph.D., CEO